Following Suominen's profit warning on 15 October, we cut our estimates, which results in a slightly...
Insplorion has signed an LoI with Mann Tek, a major manufacturer of couplings for fluids and gases.
Redeye comments on Faron’s updated BEXMAB data presented at the ESMO 2025 congress, which further st...
Redeye comments on Active Biotech’s proposed fully guaranteed rights issue of SEK70m, which is large...
YIT reports its Q3 results on October 30th. The quarter is expected to be quite slow, with housing u...
We maintain our estimates intact ahead of Relais Q3 report.
Redeye anticipates a pronounced decline in Xbrane’s share at market open.
* Q3 sales lower than expected (-5% vs. ABGSCe) * Major untapped potential in Recycling * Long-term ...
Redeye is positive about the acceptance of Paxman’s PLCS system for CIPN into the FDA’s Safer Techno...
Following the positive profit warning on 13 October, we nudge up our 2025-27 estimates by 3-5%.
* Finland-based GRK Infra raises its 2025 guidance * Sees EUR 57m-64m earnings, up ~20% from previou...
* Q3 report due 23 October; we cut '25e-'27e EPS by ~2% * We expect further margin and cash flow rec...
Redeye notes an interesting press release from Genovis confirming a SEK11m order from a global pharm...
Redeye adjusts its fair value range following the announcement of the rights issue.
Administer announced a second intended acquisition from Sarastia, this time targeting the financial ...
* Sales -5%, adj. EBIT SEK -2m vs. ABGSCe * Seasonal effects impacted Aesthetics segment * Recycling...
DT reports Q3 results on Oct 30. Q3 will be another weak quarter, while Q4 could be relatively bette...
Sales -18% vs. ABGSCe, EBIT SEK 11m vs. ABGSCe 16m* Newbuild market down 50% y-o-y, affecting growth...
Redeye comments on Xbrane following yesterday’s press release, which provided updates on a condition...
Redeye updates its view on Xspray following last week’s CRL delaying the approval of Dasynoc.